Early years of biological agents therapy in Crohn's disease and risk of the human polyomavirus JC reactivation

Journal of Cellular Physiology

Volumn 224, Issue 2, 2010, Pages 316-326

  Bellizzi, Anna ^a   Barucca, Valentina ^a   Fioriti, Daniela ^b   Colosimo, Maria T ^a   Mischitelli, Monica ^a,c   Anzivino, Elena ^a   Chiarini, Fernanda ^a   Pietropaolo, Valeria ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ADALIMUMAB; ALICAFORSEN; AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BIOLOGICAL FACTOR; CALCIUM; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; IRON; MERCAPTOPURINE; METHOTREXATE; METRONIDAZOLE; MONOCLONAL ANTIBODY IDEC 131; MULTIVITAMIN; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; OKT 4; PREBIOTIC AGENT; PROBIOTIC AGENT; RECOMBINANT INTERLEUKIN 11; RECOMBINANT PROTEIN; SALAZOSULFAPYRIDINE; UNINDEXED DRUG; VEDOLIZUMAB;

BIOLOGICAL THERAPY; BLOOD ANALYSIS; BONE MARROW SUPPRESSION; BRAIN DISEASE; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL FEATURE; CLINICAL TRIAL; COLONOSCOPY; CROHN DISEASE; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DEMYELINATION; DIET SUPPLEMENTATION; DIET THERAPY; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; ENTERITIS; ENVIRONMENTAL FACTOR; FECES ANALYSIS; GASTROINTESTINAL SURGERY; GASTROSTOMY; HEART FAILURE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOTHESIS; IMMUNE RESPONSE; INFECTION; INFUSION RELATED REACTION; IRON DEFICIENCY ANEMIA; JC VIRUS; LUPUS ERYTHEMATOSUS; LYMPHOCYTOPENIA; LYMPHOMA; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PANCREATITIS; PATHOGENESIS; PATHOPHYSIOLOGY; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; RELAPSE; REVIEW; RISK FACTOR; SENSORY NEUROPATHY; SEROCONVERSION; SMOKING; TOXIC HEPATITIS; TREMOR; ULCERATIVE COLITIS; VIRUS REACTIVATION; X RAY; BIOLOGICAL MODEL; PHYSIOLOGY; VIRUS ACTIVATION;

JC POLYOMAVIRUS;

BIOLOGICAL THERAPY; CROHN DISEASE; HUMANS; JC VIRUS; MODELS, BIOLOGICAL; RISK FACTORS; VIRUS ACTIVATION;

EID: 77953623749     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22146     Document Type: Review

References (143)

1. Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H. 2002. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 123: 679-688.
2. Alber G, Al-Robaiy S, Kleinschek M, Knauer J, Krumbholz P, Richter J, Schoeneberger S, Schuetze N, Schulz S, Toepfer K, Voigtlaender R, Lehmann J, Mueller U. 2006. Induction of immunity and inflammation by interleukin-12 family members. Ernst Schering Res Found Workshop 56: 107-127.
3. Ardizzone S, Bianchi Porro G. 2002. Inflammatory bowel disease: New insights into pathogenesis and therapy. J Intern Med 252: 475-496.
4. Ardizzone S, Samolvico F, Bollani S, Imbesi V, Elisabetta Colombo E, Bianchi Porro G. 2001. Azathioprine is more effective than oral 5-ASA in the treatment of steroid-dependent ulcerative colitis. Gastroenterology 120: A127.
5. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Romanus V, Klareskog L, Feltelius N. 2005. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52: 1986-1992.
6. Azzi A, De Santis R, Ciappi S, Leoncini F, Sterrantino G, Marino N, Mazzotta F, Laszlo D, Fanci R, Bosi A. 1996. Human polyomaviruses DNA detection in peripheral blood leukocytes from immunocompetent and immunocompromised individuals. J Neurovirol 2: 411-416.
7. Berger JR, Koralnik U. 2005. Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences. N Engl J Med 353: 362-368.
8. Bernstein CN, Rawsthorne P, Cheang M, Blanchard JF. 2006. A population-based case control study of potential risk factors for IBD. Am J Gastroenterol 101: 993-1002.
9. Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME. 2008. The emergence of progressive multifocal leukoencephalopathy(PML) in rheumatic diseases. J Autoimmun 30: 90-98.
10. Bosani M, Ardizzone S, Porro GB. 2009. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics 3: 77-97.
11. Bourreille A, Doubremelle M, de la Bletiere DR, Segain JP, Toquet C, Buelow R, Galmiche JP. 2003. RDP58, a novel immunomodulatory peptide with anti-inflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn's disease. Scand J Gastroenetrol 38: 526-532.
12. Breedveld FC. 2000. Therapeutic monoclonal antibodies. Lancet 355: 735-740.
13. Brown SJ, Mayer L. 2007. The immune response in inflammatory bowel disease. Am J Gastroenterol 102: 2058-2069.
14. Butcher EC, Picker LJ. 1996. Lymphocyte homing and homeostasis. Science 272: 60-66.
15. Calabrese LH, Molloy ES, Huang DR, Ransohoff RM. 2007. Progressive multifocal leukoencephalopathy in rheumatic diseases. Arthritis Rheum 56: 2116-2128.
16. Canva-Delcambre V, Jacquot S, Robinet E, Lémann M, Drouet C, Labalette M, Dessaint JP, Bengoufa D, Rabian C, Modigliani R, Wijdenes J, Revillard JP, Colombel JF. 1996. Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody. Aliment Pharmacol Ther 10: 721-727.
17. Chapagain ML, Verma S, Mercier F, Yanagihara R, Nerurkar VR. 2007. Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2A. Virology 364: 55-63.
18. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. 2007. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 132: 52-65.
19. Comerford LW, Bickston SJ. 2004. Treatment of luminal and fistulizing Crohn's disease with infliximab. Gastroenterol Clin N Am 3: 387-406.
20. Creed TJ, Norman MR, Probert CS, Harvey RF, Shaw IS, Smithson J, Anderson J, Moorghen M, Gupta J, Shepherd NA, Dayan CM, Hearing SD. 2003. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 18: 1865-1875.
21. Danese S, Scaldaferri F, Vetrano S, Stefanelli T, Graziani C, Repici A, Ricci R, Straface G, Sgambato A, Malesci A, Fiocchi C, Rutella S. 2007. Critical role of CD40 CD40 ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Gut 56: 1248-1256.
22. Delbue S, Guerini FR, Mancuso R, Caputo D, Mazziotti R, Saresella M, Ferrante P. 2007. JC virus viremie in interferon-beta-treated and untreated Italian multiple sclerosis patients and healthy controls. J Neurovirol 13: 73-77.
23. D'Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, Peeters M, Vermeire S, Penninckx F, Nevens F, Hiele M, Rutgeerts P. 2001. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 120: 1323-1329.
24. Drossman DA. 1998. Presidential address: Gastrointestinal illness and the biopsychosocial model. Psychosom Med 60: 258-267.
25. Du Pasquier RA, Autissier P, Zheng Y, Jean-Jacques J, Koralnik IJ. 2005. Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: Rationale for immune-based therapeutic strategies. AIDS 19: 2069-2076.
26. Dumont FJ. 2002. IDEC-131. IDEC/Eisai. Curr Opin Investig Drugs 3: 725-734.
27. Eigler A, Sinha B, Hartmann G, Endres S, 1997. Taming TNF: Strategies to restrain this proinflammatory cytokine. Immunol Today 18: 487-492.
28. Elan and Biogen Idec Announce. 2004. Elan and Biogen Idec announce ANTEGREN-natalizumab- phase III maintenance trial in Crohn's disease met its primary endpoint. Accessed on December 3, 2008. Available from: htpp://www.elan.com.
29. Elfaitouri A, Hammarin AL, Blomberg J. 2006. Quantitative real-time PCR assay for detection of human polyomavirus infection. J Virol Methods 135: 207-213.
30. +-cell depletion. Gastroenterology 108: A815.
31. Esters N, Pierik M, van Steen K, Vermeire S, Claessens G, Joossens S, Vlietinck R, Rutgeerts P. 2004. Transmission of CARD15 (NOD2) variants within families of patients with inflammatory bowel disease. Am J Gastroenterol 99: 299-305.
32. Faubion WA, Jr., Loftus EV, Jr., Harmsen WS, Zinsmeister AR, Sandborn WJ. 2001. The natural history of corticosteroid therapy for inflammatory bowel disease: A population based study. Gastroenterology 123: 255-260.
33. Feagan BG, Greenberg G, Wild G, McDonald JWD, Fedorak R, Pare P, Kishimoto K, Gutierrez-Ramos JC, Krop J. 2003. Efficacy and safety of humanized alpha4 beta7 antibody in active Crohn's disease. Gastroenterology 124: A25.
34. Fedorak NR, Nielsen OH, Williams NC, Malchow H, Forbes A, Stein B,Wild GE, Lashner B, Renner EL, Buchman A, Hardi R. 2001. Human recombinant interleukin-10 is safe and well tolerated but does not induce remission in steroid dependent Crohn's disease. Gastroenterology 120: A127.
35. Food and Drug Administration. 2006. Natalizumab (marketed as Tysabri) information. June 2006. Available at: http://www.fda.gov. Accessed July 17, 2006.
36. Friedman S. 2004. General principles of medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am 33: 191-208.
37. Fujino S, Andoh A, Bamba S, Ogawa A,Hata K, Araki Y, Bamba T, Fujiyama Y. 2003. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52: 65-70. (Pubitemid 36020767)
38. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang Z, Exley M, Kitani A, Blumberg RS, Mannon P, Strober W. 2004. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Inves 113: 1490-1497.
39. Fuss IJ, Becker C, Yang Z, Groden C, Hornung RL, Heller F, Neurath MF, Strober W, Mannon PJ. 2006. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 12: 9-15.
40. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnálek P, Zádorová Z, Palmer T, Donoghue S, Natalizumab Pan-European Study Group. 2003. Natalizumab for active Crohn's disease. N Engl J Med 348: 24-32.
41. Goldberg SL, Pecora AL, Alter RS, Kroll MS, Rowley SD, Waintraub SE, Imrit K, Preti RA. 2002. Unusual viral infections (progressive multifocal leukencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peri-transplantation rituximab. Blood 99: 1486-1488.
42. Grand RJ, Ramakrishna J, Calenda KA. 1996. Therapeutic strategies for pediatric Crohn's disease. Clin Investig Med 19: 373-380.
43. Hanaeur SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group. 2002. Maintenance infliximab for Crohn's disease: The ACCENT I randomized trial. Lancet 359: 1541-1549.
44. Hanauer SB, Present DH. 2003. The state of the art in themanagement of inflammatory bowel disease. Rev Gastroenterol Disord 3: 81-92.
45. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P., 2006. Human anti-TNF monoclonal antibody (Adalimumab) in Crohn's disease: the CLASSIC I trial. Gastroenterology 130: 323-333.
46. Hendrickson BA, Gokhale R, Cho JH. 2002. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 15: 79-94.
47. Herbein G, O'Brien WA. 2000. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med 223: 241-257.
48. Herman J, Van Ranst M, Snoeck R, Beuselinck K, Lerut E, Van Damme-Lombaerts R. 2004. Polyomavirus infection in pediatric renal transplant recipients: Evaluation using a quantitative real-time PCR technique. Pediatr Transplantation 8: 485-492.
49. Herrlinger K, Witthoeft T, Raedler A, Bokemeyer B, Krummenerl T, Schulzke JD, Boerner N, Kueppers B, Emmrich J, Mescheder A, Schwertschlag U, Shapiro M, Stange EF. 2006. Randomized, double-blind, double-blind, controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am J Gastroenterol 101: 793-797.
50. Hommes DW, Baert F, Van Assche G, Caenepeel F, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Rutgeerts P, Feagan B, D'Haens G. 2005. Management of recent onset Crohn's disease: A controlled, randomized trial comparing step-up and top-down therapy. Gastroenterology 129: 371.
51. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower- Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411: 599-603.
52. Hunter CA. 2005. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 5: 521-531.
53. Hyrich K, Symmons D, Watson K, Silman A, BSRBR Control Centre Consortium, British Society for Rheumatology Biologics Register. 2006. Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: Results from a national patient register. Ann Rheum Dis 65: 895-898.
54. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Tadamitsu Kishimoto T. 2003. Effective treatment of active Crohn's disease with humanized monoclonal antibody MRA to interleukin-6 receptor: A randomized placebo-controlled trial. Gastroenterology 124: A25.
55. Khalili K, White MK, Lublin F, Ferrante P, Berger JR. 2007. Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology 68: 985-990.
56. Kharfan-Dabaja MA, Ayala E, Greene J, Rojiani A, Murtagh FR, Anasetti C. 2007. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant 39: 101-107.
57. Kitamura T, Sugimoto C, Kato A, Ebihara H, Suzuki M, Taguchi F, Kawabe K, Yogo Y. 1997. Persistent JC virus (JCV) infection is demonstrated by continuous shedding of the same JCV strains. J Clin Microbiol 35: 1255-1257.
58. Kleinschmidt-De Masters BK, Tyler KL. 2005. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353: 369-374.
59. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P. 1993. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30: 1443-1453.
60. Kobayashi K, Kaneda K, Kasama T. 2001. Immunopathogenesis of delayed-type hypersensitivity. Microsc Res Tech 53: 241-245.
61. Koralnik IJ. 2006. Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? Ann Neurol 60: 162-173.
62. Koralnik IJ, Boden D, Mai VX, Lord CI, Letvin NL. 1999. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 52: 253-260.
63. Ksontini R, MacKay SLD, Moldawer LL. 1998. Revisiting the role of tumor necrosis factor a and the response to surgical injury and inflammation. Arch Surg 133: 558-567.
64. Kugathasan S, Saubermann LJ, Smith L, Kou D, Itoh J, Binion DG, Levine AD, Blumberg RS, Fiocchi C. 2007. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 56: 1696-1705.
65. Lakatos PL. 2006. Recent trends in the epidemiology of inflammatory bowel diseases: Up or down? World J Gastroenterol 12: 6102-6108.
66. Lakatos PL. 2009. Prevalence, predictors, and clinical consequences of medical adherence in IBD: How to improve it? World J Gastroenterol 15: 4234-4239.
67. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. 2005. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353: 375-381.
68. Lim WC, Hanauer SB. 2004. Emerging biologics therapies in inflamatory bowel disease. Rev Gastroenterol Disord 4: 66-85.
69. Lima MA, Marzocchetti A, Autissier P, Tompkins T, Chen Y, Gordon J, Clifford DB, Gandhi RT, Venna N, Berger JR, Koralnik IJ. 2007. Frequency and phenotype of JC virus specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy. J Virol 81: 3361-3368. (Pubitemid 46456645)
70. Ling PD, Lednicky JA, Keitel WA, Poston DG, White ZS, Peng R, Liu Z, Mehta SK, Pierson DL, Rooney CM, Vilchez RA, Smith EO, Butel JS. 2003. The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: A 14-month longitudinal study. J Infect Dis 187: 1571-1580.
71. Loftus EV, Sandborn WJ. 2002. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 31: 1-20.
72. Lundstig A, Stattin P, Persson K, Sasnauskas K, Viscidi RP, Gislefoss RE, Dillner J. 2007. No excess risk for colorectal cancer among subjects seropositive for the JC polyomavirus. Int J Cancer 121: 1098-1102.
73. MacDonald TT, Monteleone G, Pender SLF. 2000. Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol 51: 2-9.
74. Maginnis MS, Atwood WJ. 2009. JC virus: An oncogenic virus in animals and humans? Semin Cancer Biol 19: 261-269.
75. Major EO. 2010. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 61: 8.1-8.13.
76. Major EO, Amemiya K, Tornatore CS, Houff SA, Berger JR. 1992. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 5: 49-73.
77. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W. 2004. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 35: 2069-2079.
78. Mayer L. 2010. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol 45: 9-16.
79. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN. 2001. Demyelination occurring during anti-tumor necrosis factor a therapy for inflammatory arthritides. Arthritis Rheum 44: 2862-2869.
80. Monteleone G, Trapasso F, Parrello T, Biancone L, Stella A, Iuliano R, Luzza F, Fusco A, Pallone F. 1999. Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol 163: 143-147.
81. Niv Y, Goel A, Boland CR. 2005. JC virus and colorectal cancer: A possible trigger in the chromosomal instability pathway. Curr Opin Gastroenterol 21: 85-89.
82. Olives JP, Breton A, Hugot JP, Oksman F, Johannet C, Ghisolfi J, Navarro J, Cezard JP. 1997. Antineutrophil cytoplamic antibodies in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 25: 142-148.
83. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. 1971. Cultivation of papovalike virus from human brain with progressive multifocal leucoencephalopathy. Lancet 19: 1257-1260.
84. Papadakis KA, Targan SR. 2000. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 51: 289-298.
85. Papadakis KA, Treyzon L, Abreu MT, Fleshner PR, Targan SR, Vasiliauskas EA, 2003. Infliximab in the treatment of medically refractory indeterminate colitis Aliment Pharmacol Ther 18: 741-747.
86. Pearson DC, May GR, Fick GH, Sutherland LR. 2000. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2: CD000067.
87. Peltekova VD, Wintle RF, Rubin LA, Amos CI, Huang Q, Gu X, Newman B, Van Oene M, Cescon D, Greenberg G, Griffiths AM, St George-Hyslop PH, Siminovitch KA. 2004. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 36: 471-475.
88. Pizarro TT, Michie MH, Bentz M, Woraratanadharm J, Smith MF, Jr., Foley E, Moskaluk CA, Bickston SJ, Cominelli F. 1999. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: Expression and localization in intestinal mucosal cells. J Immunol 162: 6829-6835.
89. Plevy SE, Salzberg BA, Van Assche G. 2007. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, for treatment of severe steroid-refractory ulcerative colitis. Gastroenterology 133: 1414-1422.
90. Power C, Gladden JG, Halliday W, Del Bigio MR, Nath A, Ni W, Major EO, Blanchard J, Mowat M. 2000. AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurology 54: 743-746.
91. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 1989. 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity. Ann Intern Med 111: 641-649.
92. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJH. 1999. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340: 1398-1405. (Pubitemid 29205403)
93. Reiff C, Kelly D. 2010. Inflammatory bowel disease, gut bacteria and probiotic therapy. Int J Med Microbiol 300: 25-33.
94. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, Green T, Kuballa P, Barmada MM, Datta LW, Shugart YY, Griffiths AM, Targan SR, Ippoliti AF, Bernard EJ, Mei L, Nicolae DL, Regueiro M, Schumm LP, Steinhart AH, Rotter JI, Duerr RH, Cho JH, Daly MJ, Brant SR. 2007. Genome-wide association study identifies new susceptibility loci for Crohn's disease and implicates autophagy in disease pathogenesis. Nat Genet 39: 596-604.
95. Roos JCP, Oster AJK. 2006. Anti-tumour necrosis factor a therapy and the risk of JC virus infection. Arthritis Rheum 54: 381-382.
96. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. 1998. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 115: 822-829.
97. Rutgeerts P, D'Haens G, Targan SR, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, De-Woody KL, Schaible TF, Van Deventer SJH. 1999. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) tomaintain remission in Crohn's disease. Gastroenterology 117: 761-769.
98. Rutgeerts P, Reinisch W, Colombel JF, Gendre JP, van Deventer S, Oldenburg B, Modigliani R, Layug B, Cheng M, O'Connor J, Levitt D. 2002. Preliminary results of a phase I/II study of Huzaf, an anti-IFN-monoclonal antibody, in patients with moderate to severe active Crohn's disease. Gastroenterology 122: A61.
99. Rutgeerts P, Lemmens I, van Assche G, Noman M, Borghini-Fuhrer I, Goedkoop R. 2003. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumor necrosis factor receptor): Results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 17: 185-192.
100. Rutgeerts P, Sandborn WJ, Fedorak RN, Rachmilewitz D, Tarabar D, Gibson P, Haagen Nielsen O, Wild G, Schreiber S, Pena Rossi C, Zignani M. Onercept Study Group. 2006. Onercept for moderateto-severe-Crohn's disease: A randomized, double-bind, placebocontrolled trial. Clin Gastroenterol Hepatol 4: 888-893.
101. Sabath BF, Major EO. 2002. Traffic of JC virus from sites of initial infection to the brain: The path to progressive multifocal leukoencephalopathy. J Infect Dis 186: S180-S186.
102. Saketkoo LA, Espinoza LR. 2006. Impact of biologic agents on infectious diseases. Infect Dis Clin North Am 20: 931-961.
103. Sandborn WJ. 2001. Transcending conventional therapies: The role of biologic and other novel therapies. Inflamm Bowel Dis 1: 9-16.
104. Sandborn WJ, Faubion WA. 2004. Biologics in inflammatory bowel disease: How much progress have we made? Gut 53: 1366-1373.
105. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR, CDP571 Crohn's Study Disease Group, 2001a An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomised, palcebo-controlled trial. Gastroenterology 120: 1330-1338.
106. Sandborn WJ, Feagan BG. 2003. Mild to moderate Crohn's disease-defining the basis for a new treatment algorithm. Aliment Pharmacol Ther 18: 263-277.
107. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR, 2001b Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121: 1088-1094.
108. Sandborn WJ, Targan SR. 2002. Biologic therapy of inflammatory bowel disease. Gastroenterology 122: 1592-1608.
109. Sandborn WJ, Yednock TA. 2003. Novel approaches to treating inflammatory bowel disease: Targeting alpha-4 integrin. Am J Gastroenterol 98: 2372-2382.
110. Sandborn WJ, Hanauer SB, Loftus EV, Loftus EV, Jr., Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. 2004. An open-label study ofn the human anti-TNF monoclonal antibody adalimumab subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99: 1984-1989.
111. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P, International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group, Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. 2005. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353: 1912-1925.
112. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R. 2007a. PRECISE 1 study investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357: 228-238.
113. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. 2007b. Adalimumab for maintenence treatment of Crohn's disease: Results of the CLASSIC II trial. Gut 56: 1232-1239. (Pubitemid 47300424)
114. Sands BE. 1997. Biologic therapy for inflammatory bowel disease. Inflamm Bowel Dis 3: 95-113.
115. Sands BE, Winston B, Salzberg B, Safdi M, Barish C, Wruble L, Wilkins R, Shapiro M, Schwertschlag US. 2002. Randomized, controlled trial of recombinant human interleukin 11 in patients with active Crohn's disease. Aliment Pharmacol Ther 16: 399-406.
116. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. 2004. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350: 876-885. (Pubitemid 38252535)
117. Sarzi Puttini P, Ardizzone S, Manzionna G, Atzeni F, Colombo E, Antivalle M, Carrabba M, Bianchi-Porro G. 2003. Infliximab induced lupus in Crohn's disease: A case report. Dig Liver Dis 35: 814-817.
118. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. 1995. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7: 251-259.
119. Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, Jacyna M, Lashner BA, Gangl A, Rutgeerts P, Isaacs K, van Deventer SJ, Koningsberger JC, Cohard M, LeBeaut A, Hanauer SB. 2000. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Gastroenterology 119: 1462-1472.
120. Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, Hahn EG, Krummenerl T, Steinmann G, German ICAM-1 Study Group. 2001. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 120: 1339-1346.
121. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, PRECISE 2 Study Investigators. 2007. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357: 239-250.
122. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E. 2000. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289: 1352-1355.
123. Stein RB, Hanauer SB. 1999. Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am 28: 297-321.
124. Strieter RM, Belperio JA, Keane MP. 2003. Host innate defenses in the lung: The role of cytokines. Curr Opin Infect Dis 16: 193-198.
125. Stronkhorst A, Radema S, Yong SL, Bijl H, ten Berge IJ, Tytgat GN, van Deventer SJ. 1997. CD4 antibody treatment in patients with active Crohn's disease: A phase I dose finding study. Gut 40: 320-327.
126. Stuve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK. 2006. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab treated patients with multiple sclerosis. Arch Neurol 63: 1383-1387.
127. Sullivan KE. 2003. Regulation of inflammation. Immunol Res 27: 529-538.
128. Sweet TM, Del Valle L, Khalili K. 2002. Molecular biology and immunoregulation of human neurotropic JC virus in CNS. J Cell Physiol 191: 249-256.
129. Van Assche G, Pearce T. 2004. Fontolizumab (Huzaftm), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn's disease. Gut 53: A48.
130. Van Assche G, Dalle I, Noman M, Aerden I, Swijsen C, Asnong K, Maes B, Ceuppens J, Geboes K, Rutgeerts P. 2003. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenetrol 98: 369-376.
131. Van AsscheG, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P. 2005. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353: 362-368.
132. Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames RS. 2006. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: A randomised, double blind, placebo-controlled, dose ranging trial. Gut 55: 1568-1574.
133. van Deventer SJ. 1999. Targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease the mechanisms of action of infliximab. Aliment Pharmacol Ther 13: 3-8.
134. van Deventer SJ. 2000. Immunotherapy of Crohn's disease. Scand J Immunol 51: 18-22.
135. van Deventer SJ, Tami JA, Wedel MK. 2004. A randomised, controlled, double-bind, escalating dose study of alicaforsen enema in ulcerative colitis. Gut 53: 1646-1651.
136. Van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. 1995. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109: 129-135.
137. Verbeeck J, Van Assche G, Ryding J, Wollants E, Rans K, Vermeire S, Pourkarim MR, Noman M, Dillner J, Van Ranst M, Rutgeerts P. 2008. JC viral loads in patients with Crohn's disease treated with immunosuppression: Can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 57: 1393-1397.
138. Watzinger F, Suda M, Preuner S, Baumgartinger R, Ebner K, Baskova L, Niesters HG, Lawitschka A, Lion T. 2004. Real-time quantitative PCR assays for detection and monitoring of pathogenic human viruses in immunosuppressed pediatric patients. J Clin Microbiol 42: 5189-5198.
139. Weaver CT, Hatton RD, Mangan PR, Harrington LE. 2007. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 25: 821-852.
140. Weiss B, Shamir R, Bujanover Y, Waterman M, Hartman C, Fradkin A, Berkowitz D, Weintraub I, Eliakim R, Karban A. 2004. NOD2/CARD15 mutation analysis and genotype-phenotype correlation in Jewish pediatric patients compared with adults with Crohn's disease. J Pediatr 145: 208-212.
141. White MK, Safak M, Khalili K. 2009. Regulation of gene expression in primate polyomaviruses. J Virol 83: 10846-10856.
142. Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, Tami J, Yu R, Gibiansky E, Shanahan WR. 2002. Double-blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 51: 30-36.
143. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jäger HR, Clifford DB. 2006. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354: 924-933.